Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Neal Bhatia, Jayme Heim, Brad Schenkel & J. Gabriel Vasquez. (2023) Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis. Journal of Dermatological Treatment 34:1.
Read now
Read now
Matteo Megna, Nello Tommasino, Luca Potestio, Teresa Battista, Angelo Ruggiero, Matteo Noto, Gabriella Fabbrocini & Lucia Genco. (2022) Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. Journal of Dermatological Treatment 33:6, pages 2813-2820.
Read now
Read now
Marco Galluzzo, Andrea Chiricozzi, Elisa Cinotti, Giovanna Brunasso, Maurizio Congedo, Maria Esposito, Chiara Franchi, Giovanna Malara, Alessandra Narcisi, Stefano Piaserico, Rossana Tiberio, Giuseppe Argenziano, Gabriella Fabbrocini & Aurora Parodi. (2022) Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opinion on Biological Therapy 22:3, pages 367-376.
Read now
Read now
Charlotte Näslund-Koch, Claus Zachariae & Lone Skov. (2020) Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis. Therapeutics and Clinical Risk Management 16, pages 903-916.
Read now
Read now
Articles from other publishers (10)
Sonsoles Berenguer‐Ruiz, Mario Aparicio‐Domínguez, Pedro Herranz‐Pinto, Ricardo Ruíz‐Villaverde, Anna López‐Ferrer, Jorge Santos‐Juanes, Lourdes Rodríguez Fernández‐Freire, Mercedes Hospital‐Gil, Salvador Arias‐Santiago, Gregorio Carretero‐Hernández, Almudena Mateu‐Puchades, Marta Ferran, Elena del Alcázar, Sergio Santos‐Alarcón, Francisco Javier Garcia‐Latasa de Aranibar, Isabel Belinchón‐Romero, Álvaro González‐Cantero, Diana Ruíz‐Genao, Noemí Eiris‐Salvado, Vicenç Rocamora‐Durán, Raquel Rivera‐Diaz, Pablo de la Cueva, Esteban Daudén, Laura Salgado‐Boquete & Mar Llamas‐Velasco. (2023) Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology 37:12, pages 2517-2525.
Crossref
Crossref
Antonio Costanzo, Mar Llamas‐Velasco, Gabriella Fabbrocini, Aldo Cuccia, Raquel Rivera‐Diaz, Kristian Gaarn Du Jardin, Ismail Kasujee, Lluís Puig & José Manuel Carrascosa. (2023) Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki & Hidemi Nakagawa. (2023) Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatology and Therapy 13:3, pages 751-768.
Crossref
Crossref
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini & Sonia Sofia Ocampo-Garza. (2023) Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. Immunologic Research.
Crossref
Crossref
Athanasios Tsianakas, Uwe Schwichtenberg, Peter Pierchalla, Torsten Hinz, Sebastian Diemert & Bernhard Korge. (2022)
Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study
TILOT
. Journal of the European Academy of Dermatology and Venereology 37:1, pages 85-92.
Crossref
Crossref
Finola M. Bruins, Maartje R. Van Acht, Inge M.G.J. Bronckers, Hans M.M. Groenewoud, Elke M.G.J. De Jong & Marieke M.B. Seyger. (2022) Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen. Acta Dermato-Venereologica, pages adv00745.
Crossref
Crossref
Esra Adışen. (2022) Interleukin-23 Inhibitors. TURKDERM, pages 61-66.
Crossref
Crossref
Alice B. Gottlieb, Richard B. Warren, Matthias Augustin, Llenalia Garcia, Christopher Cioffi, Luke Peterson, Christopher Pelligra & Valerie Ciaravino. (2021) Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. Advances in Therapy 38:10, pages 5253-5269.
Crossref
Crossref
Richard B. Warren, Alice B. Gottlieb, Joseph F. Merola, Llenalia Garcia, Christopher Cioffi, Luke Peterson, Christopher Pelligra & Valerie Ciaravino. (2021) Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials. Dermatology and Therapy.
Crossref
Crossref
Paolo Gisondi, Marina Talamonti, Andrea Chiricozzi, Stefano Piaserico, Paolo Amerio, Anna Balato, Federico Bardazzi, Piergiacomo Calzavara Pinton, Anna Campanati, Angelo Cattaneo, Paolo Dapavo, Clara De Simone, Valentina Dini, Maria C. Fargnoli, Maria L. Flori, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Ada Lo Schiavo, Piergiorgio Malagoli, Giovanna Malara, Santo R. Mercuri, Maria L. Musumeci, Luigi Naldi, Manuela Papini, Aurora Parodi, Concetta Potenza, Francesca Prignano, Franco Rongioletti, Luca Stingeni, Rossana Tiberio, Marina Venturini, Luca Bianchi, Antonio Costanzo, Francesco Cusano, Giampiero Girolomoni, Anna M. Offidani & Ketty Peris. (2021) Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatology and Therapy 11:1, pages 235-252.
Crossref
Crossref